Status: Not yet recruiting
TGD001 Treatment in Thrombotic Microangiopathies
This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.
Participants needed: 70
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: TargED Biopharmaceuticals B.V.Updated: Mar 9, 2026
Eligibility criteria
18 years old or older [+4]
Diagnosis other than TMA, which could account for the findings of thrombocytopen... [+11]